Targeted nasal vaccination provides antibody-independent protection against staphylococcus aureus

41Citations
Citations of this article
48Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Despite showing promise in preclinical models, anti-Staphylococcus aureus vaccines have failed in clinical trials. To date, approaches have focused on neutralizing/opsonizing antibodies; however, vaccines exclusively inducing cellular immunity have not been studied to formally test whether a cellular-only response can protect against infection. We demonstrate that nasal vaccination with targeted nanoparticles loaded with Staphylococcus aureus antigen protects against acute systemic S. aureus infection in the absence of any antigen-specific antibodies. These findings can help inform future developments in staphylococcal vaccine development and studies into the requirements for protective immunity against S. aureus. © The Author 2013.

Cite

CITATION STYLE

APA

Misstear, K., Mcneela, E. A., Murphy, A. G., Geoghegan, J. A., O’keeffe, K. M., Fox, J., … Lavelle, E. C. (2014). Targeted nasal vaccination provides antibody-independent protection against staphylococcus aureus. Journal of Infectious Diseases, 209(9), 1479–1484. https://doi.org/10.1093/infdis/jit636

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free